Please assess the completion status of the following clinical trial:

Trial Title: Regulation of Cervical Mucus Secretion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Normal menstrual cycles of 25-35 days in length for at least previous 3 cycles~* 21-40 years of age~* BMI \>18, \<30~* Serum P4 ≥ 3 ng/ml on single sample collected between days 18-25 of self-reported menstrual cycle~* Flexible schedule allowing morning blood draws on less than 48 hour notice~* In good general health~* Commit to remain on stable diet during study period (no changes to normal dietary habits)~* Commit to using non-hormonal contraceptive methods during study period except those prescribed in the experimental protocol~* No objections to taking study drugs~* No objections to refraining from intercourse the night before any sampling and willing to using condoms during vaginal intercourse.~Exclusion Criteria:~* Oral contraceptive use or other hormone supplement within the preceding 2 months~* Women with current cervical infection~* Evidence of abnormal cervical cytology~* Use of Paragard IUD for contraception~* Long-acting hormonal contraceptive use in the past 12 months (e.g., Depo-Provera®)~* Contraindications to study drugs~* Current or past pregnancy within the previous 6 months or currently trying to conceive~* Desiring to conceive in the next 8 months~* Breastfeeding in the past 2 months~* Diagnosed Diabetes or Metabolic Syndrome~* Current or previous use of cholesterol lowering drugs within the preceding 12 months~* Diagnosed Polycystic Ovary Syndrome~* History of, or self-reported, substance abuse~* Smoker~* Previous infertility treatment excluding male factor issues~* Use of an investigational drug within the past 2 months~* History of excisional or ablative treatment procedure on cervix (ie. LEEP, Cryotherapy, Cold Knife Cone)

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- No Intervention: Spontaneous Cycle (1 month) (Type: NO_INTERVENTION): In order to qualify for the intervention phase, subjects needed to demonstrate favorable mucus at ovulation (Insler score of greater than or equal to 10 within 24h of an LH surge) and progesterone level in the luteal phase consistent with ovulation (a single P4 of greater than or equal to 3ng/ ml between days 18-35 of menstrual cycle).
- NET Arm - Norethindrone (4 months) (Type: ACTIVE_COMPARATOR): This arm will receive Norethindrone (NET) first then experience estradiol withdrawal (E2WD).~On the day prior to each admission, we instructed subjects to apply three fresh estradiol (E2) patches (0.3mg/day) to achieve mid-cycle level E2 effects.~On the day of the first and third admission, subjects were randomized to the experimental condition, either: (1) oral progestin administration (e.g., a single dose of 0.35mg norethindrone) with continuation of the E2 patches; or (2) estradiol withdrawal (e.g., removal of the patches). Subject then received the converse intervention for admissions two and four.~Subjects resumed treatment with the 0.1mg E2 patch until their next scheduled inpatient assessment. We required a minimum of five days at this level before repeating the dose escalation and the next evaluation.
- E2WD Arm - Estradiol (4 months) (Type: ACTIVE_COMPARATOR): This arm will experience estradiol withdrawal (E2WD) first and then receive Norethindrone (NET).~On the day prior to each admission, we instructed subjects to apply three fresh estradiol (E2) patches (0.3mg/day) to achieve mid-cycle level E2 effects.~On the day of the first and third admission, subjects were randomized to the experimental condition, either: (1) oral progestin administration (e.g., a single dose of 0.35mg norethindrone) with continuation of the E2 patches ; or (2) estradiol withdrawal (e.g., removal of the patches). Subject then received the converse intervention for admissions two and four.~Subjects resumed treatment with the 0.1mg E2 patch until their next scheduled inpatient assessment. We required a minimum of five days at this level before repeating the dose escalation and the next evaluation.

Based on this trial design, predict the completion outcome and termination type (if applicable).